

TERCICA INC  
Form 4  
October 18, 2006

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Ipsen, S.A.

(Last) (First) (Middle)

C/O GENERAL COUNSEL, 42,  
RUE DU DOCTEUR BLANCHE

(Street)

PARIS, IO 75016

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
TERCICA INC [TRCA]

3. Date of Earliest Transaction  
(Month/Day/Year)  
10/13/2006

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_X\_\_\_ 10% Owner  
\_\_\_ Officer (give title below) \_\_\_ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_\_\_ Form filed by One Reporting Person  
\_X\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				(A) or (D) Price			
COMMON STOCK, PAR VALUE \$0.001 <sup>(1)</sup>	10/13/2006		P	12,527,245 A	\$ 6.17 12,527,245	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount Number Shares
FIRST SENIOR CONVERTIBLE PROMISSORY NOTE <sup>(2)</sup>	\$ 7.41 <sup>(3)</sup>	10/13/2006		P	1	<sup>(4)</sup> / <sup>(4)</sup>	COMMON STOCK	3,378 <sup>(5)</sup>
WARRANT <sup>(6)</sup>	\$ 7.41 <sup>(7)</sup>	10/13/2006		P	1	<sup>(8)</sup> / <sup>(8)</sup>	COMMON STOCK	5,026 <sup>(9)</sup>

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Ipsen, S.A. C/O GENERAL COUNSEL 42, RUE DU DOCTEUR BLANCHE PARIS, IO 75016		X		
Suraypharm, SAS 42, RUE DU DOCTEUR BLANCHE PARIS, IO 75016		X		

## Signatures

/s/ Jean-Luc Belingard FOR IPSEN,  
S.A. 10/18/2006

**\*\*Signature of Reporting Person** Date

/s/ Jean-Luc Belingard FOR  
SURAYPHARM 10/18/2006

**\*\*Signature of Reporting Person** Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Suraypharm is the owner of these shares of Common Stock.

## Edgar Filing: TERCICA INC - Form 4

- (2) Ipsen, S.A. is the owner of this Derivative Security. Pursuant to Rule 16(a)-1(4) of the Securities Exchange Act of 1934 (the "Act"), nothing in this filing shall be deemed to be an admission that Suraypharm is, for the purposes of Section 16 of the Act or otherwise, the beneficial owner of this Derivative Security.

- (3) This is the initial conversion price per share of Common Stock of Tercica, Inc.; under the terms of the First Senior Convertible Promissory Note (the "First Convertible Note"), the conversion price is subject to certain adjustments. The First Convertible Note has been described in Schedule 13D filed by Ipsen, S.A. and Suraypharm with the United States Securities and Exchange Commission, dated July 18, 2006 ("Schedule 13D")

- (4) The conversion rights under the First Convertible Note are exercisable at any time from 10/13/06.

- (5) This is the maximum number of shares of Common Stock of Tercica, Inc. that may be acquired on exercise of the conversion right under the First Convertible Note as at the date hereof. The number of shares acquired pursuant to the exercise of the conversion right under the First Convertible Note may vary from this number depending on the amount of principal due and interest accrued under the First Convertible Note in respect of which the conversion right is exercised and certain potential adjustments to the conversion price in accordance with the terms of the First Convertible Note.

- (6) Ipsen, S.A. is the owner of this Derivative Security. Pursuant to Rule 16(a)-1(4) of the Act, nothing in this filing shall be deemed to be an admission that Suraypharm is, for the purposes of Section 16 of the Act or otherwise, the beneficial owner of this Derivative Security.

- (7) This is the initial exercise price per share of Common Stock of Tercica, Inc.; under the terms of the Warrant, the conversion price is subject to certain adjustments. The Warrant has been described in Schedule 13D.

- (8) The Warrant is exercisable at any time until the expiration of a five-year period commencing on 10/13/06.

- (9) This is the maximum number of shares of Common Stock of Tercica, Inc. that may be acquired on exercise of the Warrant as at the date hereof. The number of shares acquired pursuant to the exercise of the Warrant may be increased by a variable amount as set forth in the Warrant, and is subject to possible adjustments in accordance with the terms of the Warrant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.